No Benefit to Adding ICI to Chemo in TNBC : vimarsana.com

The Michelangelo trial revealed that adding atezolizumab to nab-paclitaxel and carboplatin did not improve 5-year event-free survival in patients with triple-negative breast cancer.

Related Keywords

Milan , Lombardia , Italy , Genentech Roche , Kevin Kalinsky , Fondazione Michelangelo , Luca Gianni , European Society For Medical Oncology , European Society , Winship Cancer Institute , Emory University , Hoffman La Roche , Breast Cancer , Alignant Breast Neoplasm , Triple Negative Breast Cancer , Breast , Cancer , Alignant Neoplasia , Arcinoma , Pcr , Polymerase Chain Reaction , Biologic Therapy , Toxicology , Chemotherapy , Neoadjuvant , Surgery , Adjuvant Chemotherapy , Anthracyclines , Tumor , Receptors ,